TEVA - Teva Pharmaceutical Industries Limited

NYSE - Nasdaq Real Time Price. Currency in USD
22.51
-0.11 (-0.47%)
As of 11:38AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close22.62
Open22.49
Bid22.47 x 800
Ask22.49 x 800
Day's Range22.33 - 22.82
52 Week Range12.71 - 25.96
Volume2,224,419
Avg. Volume12,325,792
Market Cap22.936B
Beta (3Y Monthly)0.93
PE Ratio (TTM)N/A
EPS (TTM)-10.09
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2017-11-27
1y Target Est23.19
Trade prices are not sourced from all markets
  • Why Teva Pharmaceutical Is Up 20% in 2018 So Far
    Motley Fool2 hours ago

    Why Teva Pharmaceutical Is Up 20% in 2018 So Far

    Find out how the struggling generic drugmaker outperformed the market this year.

  • Migraine-Focused Biotech Has A Headache On Quarterly Losses
    Investor's Business Daily2 days ago

    Migraine-Focused Biotech Has A Headache On Quarterly Losses

    Biohaven Pharmaceutical slumped to a three-week low Wednesday after the biotech reported greater-than-expected third-quarter losses.

  • Benzinga2 days ago

    Jim Cramer Weighs In On Dropbox, Teva And More

    On CNBC's "Mad Money Lightning Round" , Jim Cramer said he would stay away from Sociedad Quimica y Minera de Chile (NYSE: SQM ). He doesn't see any edge that could make him money in the stock. ...

  • CNBC3 days ago

    Cramer's lightning round: Dropbox's stock is a buy even after the tech sell-off

    Jim Cramer flags an opportunity in shares of data-focused technology play Dropbox in the lightning round.

  • Jazz Pharmaceuticals: How Are Xyrem and Erwinaze Positioned?
    Market Realist3 days ago

    Jazz Pharmaceuticals: How Are Xyrem and Erwinaze Positioned?

    Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $357.3 million in the third quarter—compared to $303.9 million in the third quarter of 2017, which reflected ~18% YoY (year-over-year) growth. Xyrem’s net revenues over the first nine months of 2018 amounted to $1.0 billion—compared to $874.2 million in the same period in 2017, which reflects 18% YoY growth.

  • 4 Stocks Warren Buffett and Insiders Are Piling On
    Insider Monkey4 days ago

    4 Stocks Warren Buffett and Insiders Are Piling On

    Warren Buffett is arguably the greatest investor of all time. Over his career, Buffett’s investing prowess formed one of the greatest conglomerates of all time and generated a lot of value for investors.  In this article, examine four stocks that Buffett’s Berkshire Hathaway held in the second quarter and that company insiders have also bought in the last […]

  • InvestorPlace8 days ago

    Even Following the Latest Surge, Mylan Stock Has Plenty of Room to Grow

    Whenever a stock shoots higher, value investors justifiably hesitate on trading it. The stock priced in the good news already, leaving few extra gains ahead. So when Mylan N.V. (NASDAQ: MYL) rose by over 15% on the week, the best thing investors may do before buying Mylan stock is to look at the quarterly earnings result in detail.

  • Amgen (AMGN) Counts on New Drugs Amid Rising Biosimilar Woes
    Zacks9 days ago

    Amgen (AMGN) Counts on New Drugs Amid Rising Biosimilar Woes

    Amgen's newer drugs, Prolia, Xgeva, Kyprolis, are driving sales. Lower sales of mature drugs like Enbrel and biosimilar competition for Neulasta/Epogen are concerns.

  • Is Teva Pharmaceutical Industries (TEVA) Outperforming Other Medical Stocks This Year?
    Zacks9 days ago

    Is Teva Pharmaceutical Industries (TEVA) Outperforming Other Medical Stocks This Year?

    Is (TEVA) Outperforming Other Medical Stocks This Year?

  • These 3 Value Stocks Are Absurdly Cheap Right Now
    Motley Fool9 days ago

    These 3 Value Stocks Are Absurdly Cheap Right Now

    You can profit big from the market's mistakes.

  • 9 High-Risk Stocks to Buy for Massive Rewards
    InvestorPlace10 days ago

    9 High-Risk Stocks to Buy for Massive Rewards

    Teva Pharmaceutical (NYSE:TEVA) is doing a lot better this year — up just shy of 20%. Its key drug, Copaxone, which treats multiple sclerosis, is facing generic competition from Mylan (NASDAQ:MYL), among others. The company has sold assets to clean up its balance sheet, which has de-risked the story somewhat.

  • How Teva Pharmaceutical’s Products Performed Internationally
    Market Realist10 days ago

    How Teva Pharmaceutical’s Products Performed Internationally

    In the third quarter, Teva Pharmaceutical’s (TEVA) revenue fell ~18% YoY (year-over-year) to $726.0 million from $882.0 million. It fell YoY to $2.3 billion in the first nine months of this year from $2.5 billion. The company’s international gross profit fell YoY to $301.0 million in the third quarter from $351.0 million, and to $942.0 million in the first nine months of this year from $1.0 billion.

  • Teva Pharmaceutical’s Performance in European Markets
    Market Realist10 days ago

    Teva Pharmaceutical’s Performance in European Markets

    In the third quarter, Teva Pharmaceutical’s (TEVA) European revenue fell ~12% YoY (year-over-year) to $1.2 billion from $1.38 billion. Its net European revenue fell YoY to $3.98 billion in the first nine months of this year from $4.02 billion.

  • How Teva’s Products Performed in North American Markets
    Market Realist10 days ago

    How Teva’s Products Performed in North American Markets

    In the third quarter, Teva Pharmaceutical’s (TEVA) North American Generic Medicines revenue fell ~25% YoY (year-over-year) to $922.0 million from $1.2 billion. In the first nine months of this year, it fell ~26% YoY to $3.0 billion from $4.0 billion.

  • A Look at Teva Pharmaceutical’s Third-Quarter Earnings
    Market Realist11 days ago

    A Look at Teva Pharmaceutical’s Third-Quarter Earnings

    Teva Pharmaceutical’s (TEVA) GAAP net income fell YoY (year-over-year) to -$273 million from $530.0 million in the third quarter, but rose YoY to $541.0 million from -$4.9 billion in the first nine months of this year. Teva’s GAAP diluted EPS fell YoY to -$0.27 from $0.52 in the third quarter, and to $0.53 from $4.85 in the first nine months of this year. The company’s non-GAAP net income and non-GAAP diluted EPS fell YoY to $694.0 million and $0.68, respectively, from $1.0 billion and $1 in the third quarter.

  • Teva Pharmaceutical’s Performance in the Third Quarter
    Market Realist11 days ago

    Teva Pharmaceutical’s Performance in the Third Quarter

    In the third quarter, Teva Pharmaceutical’s (TEVA) revenue fell ~19% YoY (year-over-year) to $4.5 billion. In the first nine months of this year, Teva’s net revenue fell ~16% YoY to $14.3 billion from $17.0 billion.

  • Barrons.com11 days ago

    These Health-Care Standouts Have More Room to Rise, Morgan Stanley Says

    Both Bausch Health Cos. and Teva Pharmaceuticals have outperformed their peers and the market this year, but Morgan Stanley sees more gains ahead.

  • How Wall Street Analysts View Teva Pharmaceutical
    Market Realist11 days ago

    How Wall Street Analysts View Teva Pharmaceutical

    In October, the FDA’s Oncologic Drugs Advisory Committee unanimously voted to recommend approving Teva Pharmaceutical’s (TEVA) and Celltrion’s Biologics License Application for CT-P10, a proposed biosimilar to Roche’s (RHHBY) Rituxan. The recommended approval of CT-P10 was for three indications: as a monotherapy for relapsed or refractory B-cell non-Hodgkin’s lymphoma as a first-line treatment for B-cell NHL in combination with chemotherapy as a second-line monotherapy for non-progressing B-cell NHL after cyclophosphamide-, vincristine-, or prednisone-based chemotherapy

  • Benzinga11 days ago

    Teva To Deliver Cost Cuts, Earnings Surprise In Coming Years, Morgan Stanley Says In Upgrade

    Teva Pharmaceutical Industries Ltd ADR (NYSE: TEVA ) last week reported a 19-percent drop in Q3 revenues, stung by generic competition to its multiple sclerosis drug Copaxone, price erosion at its U.S. ...

  • ACCESSWIRE11 days ago

    Monday's Top Healthcare Stocks To Watch Ahead Of Elections

    Healthcare has become the latest market to take full advantage of this trend. According to a paper by PwC called The Digital Healthcare Leap, the new trends are ripe for digital healthcare solutions in developed and emerging markets. As a result, the industry has expanded its focus to non-critical health care services to cater to this changing demand of present-day consumers.

  • Teva (TEVA) Q3 Earnings Beat, 2018 EPS View Up, Shares Rise
    Zacks14 days ago

    Teva (TEVA) Q3 Earnings Beat, 2018 EPS View Up, Shares Rise

    Teva's (TEVA) shares up 15% despite mixed third-quarter results as it increases its earnings and free cash flow guidance for the full year.

  • ACCESSWIRE14 days ago

    Today’s Research Reports on Stocks to Watch: Teva Pharmaceutical and SELLAS Life Sciences

    NEW YORK, NY / ACCESSWIRE / November 2, 2018 / Teva shares were skyrocketing on a third quarter financial report that beat analysts’ estimates and a raised outlook. Shares of Sellas Life Sciences were ...

  • The Wall Street Journal15 days ago

    [$$] Teva Passes Its Check-Up

    The generic drug giant reported third-quarter sales of $4.5 billion and adjusted earnings of 68 cents a share. While both figures were down significantly from a year earlier, the earnings figure topped expectations thanks to deeper cost cuts than analysts had anticipated. Teva also increased its full-year guidance for profit and free cash flow.

  • Why Teva Pharmaceutical Industries Ltd. Stock Crushed It Today
    Motley Fool15 days ago

    Why Teva Pharmaceutical Industries Ltd. Stock Crushed It Today

    Teva's comeback continues to take shape.

  • Why Las Vegas Sands, DowDuPont, and Teva Pharmaceutical Industries Jumped Today
    Motley Fool15 days ago

    Why Las Vegas Sands, DowDuPont, and Teva Pharmaceutical Industries Jumped Today

    Find out which of these stocks climbed on strong earnings.